Innovative Medicine
-
-
Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety -
-
-
Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
Encouraging Data from a Phase 1b/2, Open-label, Multicenter Study -
Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
Sub-Saharan African Ministries of Health Invited to Submit Expression of Interest to Participate in New EffortDonation Program to be Part of Broader Initiative to Raise Awareness and Action -
New VELCADE® Data Highlight Treatment’s Versatility And Its Continued Role As A Backbone Of Multiple Myeloma Therapy
Studies affirm benefits of VELCADE (bortezomib) therapy regarding survival, disease progression, safety and quality of life in multiple myeloma, in both monotherapy and combination therapy -
Janssen Pharmaceutica NV Extends Commitment to Global Mental Health Scholarships as Part of Its Healthy Minds Programme
Funding to British schools continues meaningful aid for future leaders in mental health research, policy and practice -
New Data at American Society of Hematology (ASH) Annual Meeting Will Offer Important Insights into Safe and Efficacious Use of XARELTO®
XARELTO® is the Most Prescribed Novel Oral Anticoagulant in the U.S. Market Today